Eslicarbazepine Acetate Tablet
Product Images NDC 51407-780

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 51407-780). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-779-30lb (Eslicarbazepine Acetate 200mg)

This is the product information for a medication called Eslicarbazapine acetate in tablet form, with each tablet containing 200 mg of the active ingredient. The dosage instructions and storage information are provided, including keeping the tablets in a tight container, away from children at a temperature range between 20°C to 25°C (68°F to 77°F). The medication is prescribed by a healthcare provider and it is important to refer to the package insert for further details. The medicine is distributed by GSMS, Inc in Camarillo, California.*

FDA Label Image

51407-780-30lb (Eslicarbazepine Acetate 400mg)

This text provides information about a medication called Eslicarbazepine tablets, with a dosage of 400mg. It includes instructions to keep the tablets in a tight container, store them between 15°C to 30°C, and dispense them with the Medication Guide for each patient. The text also mentions a website for more information and indicates it is marketed in the USA.*

FDA Label Image

51407-781-60lb (Eslicarbazepine Acetate 600mg)

FDA Label Image

51407-782-30lb (Eslicarbazepine Acetate 800mg)

This text provides information about Eslicarbazepine Acetate Tablets, with each tablet containing 800 mg of the active ingredient. It includes directions for use, storage recommendations, dosage information, and manufacturer details. The NDC number for the product is 51407-782-30. This medication is typically taken once daily as indicated in the package insert.*

FDA Label Image

Figure1.jpg (Figure1)

FDA Label Image

Figure2.jpg (Figure2)

This appears to be a report on fold change and 908 cycle threshold in relation to a specific study or experiment. The text suggests a recommendation for a higher dose of elicarbazepine or primidone.*

FDA Label Image

Figure3a.jpg (Figure3)

FDA Label Image

Figure3b.jpg (Figure3b)

This text discusses changes in fold change and provides recommendations related to the use of statins, oral contraceptives, and other drugs. It mentions adjusting the dose of simvastatin and rosuvastatin based on clinically significant changes in lipid levels. It also suggests considering additional or alternative non-hormonal birth control methods. It emphasizes the importance of monitoring patients to maintain lipid levels.*

FDA Label Image

Figure4.jpg (Figure4)

FDA Label Image

Figure5.jpg (Figure5)

This text describes the reduction in seizure frequency from baseline for Esucarbazepine Acetate tablets 1200mg. The study also mentions the comparison with a placebo group in the study.*

FDA Label Image

Structure.jpg (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.